Centre d'Assistance Médicale à la Procréation et de Préservation de la Fertilité, Hôpital Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille F-59000, France.
Institut de Biologie de la Reproduction-Spermiologie-CECOS, Hôpital Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille F-59000, France.
Reprod Biomed Online. 2021 Aug;43(2):205-214. doi: 10.1016/j.rbmo.2021.04.020. Epub 2021 May 13.
What are ovarian stimulation cycle outcomes and acceptance rates of an oocyte accumulation programme in young women with benign ovarian tumour (BOT)?
Retrospective cohort study conducted at the Academic Assisted Reproductive Technology and Fertility Preservation Centre, Lille University Hospital, between January 2016 and December 2019. The number of metaphase II oocytes per cycle and per patient after accumulation were evaluated. Two groups were identified for the analysis: endometrioma ('endometrioma') and dermoid, mucinous or serous cyst ('other cysts').
A total of 113 fertility-preservation cycles were analysed in 70 women aged 27.9 ± 4.8 years. Almost all women had undergone previous ovarian surgery before fertility preservation (89%). Mean anti-Müllerian hormone levels before ovarian stimulation was 12.5 ± 8.7 pmol/l. A total of 6.4 ± 3.4 oocytes were retrieved, and 4.3 ± 3.4 metaphase II (MII) oocytes were vitrified per cycle. All agreed to the oocyte accumulation programme and all underwent at least one cycle. To date, 36 (51%) patients achieved two or three fertility- preservation cycles. After accumulation, 7.0 ± 5.23 MII oocytes were vitrified per patient. No difference was found in ovarian response and oocyte cohort between the 'endometrioma' and 'other cysts' groups. Questionnaires completed after oocyte retrieval revealed abdominal bloating and pelvic pain in most patients, with no difference according to the type of cyst. No serious adverse events occurred.
Oocyte accumulation should be systematically offered to young women with BOT irrespective of histological type, as it seems to be well-tolerated. Long-term follow-up is needed to assess the efficiency of oocyte accumulation to optimize the chances of subsequent pregnancies.
患有良性卵巢肿瘤（BOT）的年轻女性进行卵子积累方案的卵巢刺激周期结局和接受率是多少？
这项回顾性队列研究于 2016 年 1 月至 2019 年 12 月在里尔大学医院的辅助生殖技术和生育力保存中心进行。评估了每个周期和每位患者的中期 II 卵母细胞数量。为了分析，将患者分为两组：子宫内膜瘤（“子宫内膜瘤”）和皮样囊肿、黏液性或浆液性囊肿（“其他囊肿”）。
共分析了 70 名年龄 27.9 ± 4.8 岁的妇女的 113 个生育保存周期。几乎所有妇女在生育保存前都进行过卵巢手术（89%）。卵巢刺激前抗苗勒管激素水平平均为 12.5 ± 8.7 pmol/l。每个周期平均可获得 6.4 ± 3.4 个卵母细胞，每个周期平均可获得 4.3 ± 3.4 个中期 II（MII）卵母细胞。所有患者都同意卵母细胞积累方案，所有患者都至少进行了一个周期。迄今为止，36（51%）名患者已完成了两个或三个生育保存周期。积累后，每位患者可冷冻保存 7.0 ± 5.23 个 MII 卵母细胞。“子宫内膜瘤”和“其他囊肿”组之间的卵巢反应和卵母细胞群没有差异。卵母细胞回收后完成的问卷显示大多数患者出现腹部肿胀和骨盆疼痛，但根据囊肿类型无差异。未发生严重不良事件。
无论组织学类型如何，对于患有 BOT 的年轻女性，都应系统地提供卵母细胞积累方案，因为它似乎是可以耐受的。需要长期随访以评估卵母细胞积累的效率，以优化随后妊娠的机会。
